Silence Therapeutics (SLN) Deferred Taxes (2024 - 2025)
Silence Therapeutics (SLN) posted Deferred Taxes of $1000.0 for Q3 2025, down 90.0% sequentially from $10000.0 in Q2 2025, and down 97.96% YoY from $49000.0 in Q3 2024.
Silence Therapeutics (SLN) Deferred Taxes (2024 - 2025) Analysis & Trends
Silence Therapeutics has reported Deferred Taxes for 2 years, with the latest figure at $1000.0 in Q3 2025.
- Quarterly Deferred Taxes fell 97.96% year-over-year to $1000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $11000.0 (down 98.7% YoY) and the FY2025 annual result came in at $11000.0, down 98.7% from the prior year.
- Deferred Taxes slipped to $1000.0 in Q3 2025 per SLN's latest filing, from $10000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $324000.0 in Q4 2024 and troughed at $1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Dec 31, 2024 | 324,000.00 |
| Sep 30, 2024 | 49,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 244,000.00 |